1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with A-alphalipoprotein Neuropathy in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Demopoulos, CA; Kolovou, G; Kolovou, V; Papakonstantinou, VD; Stamatakis, G; Verouti, SN; Xanthopoulou, MN | 1 |
Chonn, A; Pritchard, PH; Yeung, CC | 1 |
2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and A-alphalipoprotein Neuropathy
Article | Year |
---|---|
Platelet activating factor levels and metabolism in Tangier disease: a case study.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetyltransferases; Adenosine Diphosphate; Adult; Aged; Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Assay; Blood Platelets; Coronary Artery Disease; Diacylglycerol Cholinephosphotransferase; Female; Humans; Middle Aged; Mutation; Platelet Activating Factor; Platelet Aggregation; Rabbits; Reference Values; Tangier Disease; Thrombin | 2012 |
The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease).
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Humans; Hypolipoproteinemias; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Phenotype; Phospholipases A; Phospholipases A2; Platelet Activating Factor; Tangier Disease | 1985 |